Analysis of Medicare Patients Treated with Pimavanserin versus Other Atypical Antipsychotics: A Cost-Offset Model Evaluating Skilled Nursing Facility Stays and Long-Term Care Admissions in Parkinson’s Disease Psychosis

References

• Parkinson’s Foundation. Statistics on Parkinson’s; 2023. Available from: https://www.parkinson.org/understanding-parkinsons/statistics/prevalence-incidence. Accessed June 30, 2023.
   Google Scholar
• Jankovic J. Parkinson’s disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry. 2008;79(4):368–376. doi:10.1136/jnnp.2007.131045
   PubMed Web of Science ®Google Scholar
• Martinez-Martin P, Rodriguez-Blazquez C, Kurtis MM, Chaudhuri KR; NMSS Validation Group. The impact of non-motor symptoms on health-related quality of life of patients with Parkinson’s disease. Mov Disord. 2011;26(3):399–406. doi:10.1002/mds.23462
   PubMed Web of Science ®Google Scholar
• Hermanowicz N, Edwards K. Parkinson’s disease psychosis: symptoms, management, and economic burden. Am J Manag Care. 2015;21(10 suppl):s199–s206.
   PubMed Web of Science ®Google Scholar
• Fredericks D, Norton JC, Atchison C, Schoenhaus R, Pill MW. Parkinson’s disease and Parkinson’s disease psychosis: a perspective on the challenges, treatments, and economic burden. Am J Manag Care. 2017;23(5 suppl):s83–s92.
   PubMed Web of Science ®Google Scholar
• Chang A, Fox SH. Psychosis in Parkinson’s disease: epidemiology, pathophysiology, and management. Drugs. 2016;76(11):1093–1118. doi:10.1007/s40265-016-0600-5
   PubMed Web of Science ®Google Scholar
• Schneider RB, Iourinets J, Richard IH. Parkinson’s disease psychosis: presentation, diagnosis and management. Neurodegener Dis Manag. 2017;7(6):365–376. doi:10.2217/nmt-2017-0028
   PubMed Web of Science ®Google Scholar
• Brent RJ. Life expectancy in nursing homes. Appl Econ. 2022;54(16):1877–1888. doi:10.1080/00036846.2021.1983138
   Web of Science ®Google Scholar
• Goetz CG, Stebbins GT. Mortality and hallucinations in nursing home patients with advanced Parkinson’s disease. Neurology. 1995;45(4):669–671. doi:10.1212/WNL.45.4.669
   PubMed Web of Science ®Google Scholar
• Safarpour D, Thibault DP, DeSanto CL, et al. Nursing home and end-of-life care in Parkinson disease. Neurology. 2015;85(5):413–419. Epub 2015 Jul 2. PMID: 26138947; PMCID: PMC4534080. doi:10.1212/WNL.0000000000001715
   PubMed Web of Science ®Google Scholar
• Zarowitz BJ, O’Shea T. Reassessment of the prevalence, clinical characteristics, and pharmacologic treatment of nursing facility residents with Parkinson’s disease. Consult Pharm. 2013;28(9):556–568.
   PubMedGoogle Scholar
• Mitchell SL, Kiely DK, Kiel DP, Lipsitz LA. The epidemiology, clinical characteristics, and natural history of older nursing home residents with a diagnosis of Parkinson’s disease. J Am Geriatr Soc. 1996;44(4):394–399. doi:10.1111/j.1532-5415.1996.tb06408.x
   PubMed Web of Science ®Google Scholar
• Lapane KL, Fernandez HH, Friedman JH. Prevalence, clinical characteristics, and pharmacologic treatment of Parkinson’s disease in residents in long-term care facilities. SAGE Study Group. Pharmacotherapy. 1999;19(11):1321–1327. doi:10.1592/phco.19.16.1321.30877
   PubMed Web of Science ®Google Scholar
• Wetmore JB, Li S, Yan H, et al. Increases in institutionalization, healthcare resource utilization, and mortality risk associated with Parkinson disease psychosis: retrospective cohort study. Parkinsonism Relat Disord. 2019;68:95–101. doi:10.1016/j.parkreldis.2019.10.018
   PubMed Web of Science ®Google Scholar
• Aarsland D, Larsen JP, Karlsen K, Lim NG, Tandberg E. Mental symptoms in Parkinson’s disease are important contributors to caregiver distress. Int J Geriatr Psychiatry. 1999;14(10):866–874. doi:10.1002/(SICI)1099-1166(199910)14:10<866::AID-GPS38>3.0.CO;2-Z
   PubMed Web of Science ®Google Scholar
• Martinez-Martin P, Rodriguez-Blazquez C, Forjaz MJ, et al. Neuropsychiatric symptoms and caregiver’s burden in Parkinson’s disease. Parkinsonism Relat Disord. 2015;21(6):629–634. doi:10.1016/j.parkreldis.2015.03.024
   PubMed Web of Science ®Google Scholar
• Kitten AK, Hallowell SA, Saklad SR, Evoy KE. Pimavanserin: a novel drug approved to treat Parkinson’s disease psychosis. Innov Clin Neurosci. 2018;15(1–2):16–22.
   PubMedGoogle Scholar
• Yohanna D, Cifu AS. Antipsychotics to treat agitation or psychosis in patients with dementia. JAMA. 2017;318(11):1057–1058. doi:10.1001/jama.2017.11112
   PubMed Web of Science ®Google Scholar
• Alipour-Haris G, Armstrong MJ, Okun M, Brown JD. Comparison of pimavanserin versus quetiapine for hospitalization and mortality risk among medicare beneficiaries with Parkinson’s disease psychosis. Mov Disord Clin Pract. 2023;10(3):406–414. doi:10.1002/mdc3.13652
   PubMed Web of Science ®Google Scholar
• Hwang YJ, Alexander GC, An H, Moore TJ, Mehta HB. Risk of hospitalization and death associated with pimavanserin use in older adults with Parkinson disease. Neurology. 2021;97(13):e1266–e1275. doi:10.1212/WNL.0000000000012601
   PubMed Web of Science ®Google Scholar
• Ganesh A, Galetta S, Galetta S, Ganesh A, Lewis A, Siegler JE. Editors’ note: risk of hospitalization and death associated with pimavanserin use in older adults with Parkinson disease. Neurology. 2022;98(1):48. doi:10.1212/WNL.0000000000013041
   Web of Science ®Google Scholar
• Mosholder AD, Ma Y, Akhtar S, et al. Mortality among Parkinson’s disease patients treated with pimavanserin or atypical antipsychotics: an observational study in medicare beneficiaries. Am J Psychiatry. 2022;179(8):553–561. doi:10.1176/appi.ajp.21090876
   PubMed Web of Science ®Google Scholar
• Rajagopalan K, Rashid N, Kumar S, Doshi D. Health care resource utilization patterns among patients with Parkinson’s disease psychosis: analysis of Medicare beneficiaries treated with pimavanserin or other-atypical antipsychotics. J Med Econ. 2023;26(1):34–42. doi:10.1080/13696998.2022.2152600
   PubMed Web of Science ®Google Scholar
• Kumar S, Rashid N, Doshi D, et al. Risk of long-term care admissions among medicare patients treated with pimavanserin or other atypical antipsychotics for Parkinson’s disease psychosis [abstract]. Mov Disord. 2022;37(suppl 1):2022.
   Google Scholar
• CMS. PDPM Calculation Worksheet for SNFs. Center for Medicare and Medicaid Services; 2019.
   Google Scholar
• Association AH. Skilled nursing facility PPS final rule for FY 2022; 2021. Available from: https://www.aha.org/system/files/media/file/2021/08/skilled-nursing-facility-pps-final-rule-for-fy-2022-advisory-8-26-21.pdf. Accessed January, 2023.
   Google Scholar
• (CLA) C. Skilled nursing facility PDPM PPS rate calculator; 2022.
   Google Scholar
• Layton JB, Forns J, McQuay LJ, et al. Mortality in patients with Parkinson’s disease-related psychosis treated with pimavanserin compared with other atypical antipsychotics: a cohort study. Drug Saf. 2023;46(2):195–208. doi:10.1007/s40264-022-01260-6
   PubMed Web of Science ®Google Scholar
• Yang W, Hamilton JL, Kopil C, et al. Current and projected future economic burden of Parkinson’s disease in the U.S. NPJ Parkinsons Dis. 2020;6(1):15. doi:10.1038/s41531-020-0117-1
   PubMed Web of Science ®Google Scholar